Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
View original at finance.yahoo.comLilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10th U.S…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Having modern, robust pharmaceutical manufacturing capabilities here in the United States is essential for both our national security and domestic economy
80% confidenceThis multi-billion dollar investment in the Lehigh Valley is a powerful testament to Pennsylvania's leadership in life sciences and advanced manufacturing
80% confidenceFor each manufacturing job created, several more will be generated in related sectors like supply chain, logistics and retail
80% confidenceWhen we announced our Economic Development Strategy here in the Lehigh Valley two years ago, we set out to win historic, life-changing deals like the one we're announcing with Lilly today. Before I took office, Pennsylvania wasn't even in the conversation for major investments like this
80% confidenceOur mission starts with patients and delivering the medicines they need. To meet increasing demand, we're expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next‑generation weight-loss medicines
80% confidenceFor every dollar Lilly invests, it estimates up to four dollars in additional local economic activity
80% confidencePennsylvania continues to be a leader in health care innovation, and I will always support companies like Lilly making major investments to advance these technologies
80% confidenceLilly Lehigh Valley—our newest injectable medicine and device manufacturing facility—will increase access to next-generation weight-loss treatments and improve the domestic supply of essential medicines for current and future patients
80% confidence
Cited in these Via News reports
- 68 New AI Unicorns Emerge in Early 2026 as Infrastructure Investment Accelerates →
- AI Systems Now Solve Complex Math Problems in Hours, OpenAI Targets Automated Research Labs by 2028 →
- Enterprise AI Governance Expands 97 Members as LLM Market Forecasts Signal Corporate Deployment Wave →
- OpenAI Chief Scientist Predicts 'Research Lab in Data Center' as AI Infrastructure Market Splits →
- OpenAI Chief Scientist Says AI Research Systems Now Run Experiments Without Human Intervention →
- OpenAI Pushes Fully Automated AI Researchers as Enterprise Infrastructure Spend Accelerates →
- S&P Global Acquires Enertel AI Corporation as Financial Sector Accelerates AI Integration →
